1-9 of 9
Howard Levy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1/2 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Marzeptacog Alfa (activated) in the Treatment of Episodic Bleeding in Subjects with Inherited Bleeding Disorders

Free
Linda Neuman, MD, Shraddha Desai, PhD MS, Frank Del Greco, MBA, Tom Knudsen, PhD DVM, Howard Levy, PhD MBBChir
Journal: Blood
Blood (2020) 136 (Supplement 1): 32–33.
https://doi.org/10.1182/blood-2020-137223
Published: 2020
Journal Articles

The Crimson 1 Study: A Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous Marzeptocog Alfa (activated) for on-Demand Treatment and Control of Bleeding Episodes in Subjects with Hemophilia A or Hemophilia B, with Inhibitors

Free
Linda Neuman, MD, Shraddha Desai, PhD MS, Tom Knudsen, PhD DVM, Frank Del Greco, MBA, Howard Levy, PhD MBBChir
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–40.
https://doi.org/10.1182/blood-2020-137806
Published: 2020
Journal Articles

The Combination of Marzeptacog Alfa (Activated) or Eptacog Alfa (Activated) with Emicizumab Appears Comparable As Assessed By the Thrombin Generation Test in Hemophilia a Plasma

Free
Tom Knudsen, PhD DVM, Brajesh Kumar, Frank Del Greco, MBA, Linda Neuman, MD, Howard Levy, PhD MBBChir, Grant E. Blouse, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1112.
https://doi.org/10.1182/blood-2019-130559
Published: 2019
Journal Articles

Fast Onset of Action of Subcutaneously Administered Marzeptacog Alfa (Activated) Supports on-Demand Treatment in Hemophilia a Mice

Free
Frank Del Greco, MBA, Linda Neuman, MD, Howard Levy, PhD MBBChir, Jill Reckless, Tom Knudsen, PhD DVM, Grant E. Blouse, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2420.
https://doi.org/10.1182/blood-2019-128971
Published: 2019
Journal Articles

Opportunities for Improvement: The Lot of the Inhibitor Patient Is Not a Happy One

Free
Frank V. McL. Booth, MA MSc BM BCh, Johnny Mahlangu, Howard Levy, PhD MBBChir
Journal: Blood
Blood (2018) 132 (Supplement 1): 5040.
https://doi.org/10.1182/blood-2018-99-111720
Published: 2018
Journal Articles

Phase 2/3 Trial of Subcutaneously Administered Marzeptacog Alfa (activated) an Engineered FVIIa in Hemophilia with Inhibitors - Pharmacokinetics, Pharmacodynamics, Safety and Efficacy

Free
Howard Levy, PhD MBBChir, Levani Makhaldiani, Genadi Iosava, MD, Johnny Mahlangu, Marina V Kosinova, MD, Heghine Khacchatryan, MD, Frank Del Greco, MBA, Frank V. McL. Booth, MA MSc BM BCh
Journal: Blood
Blood (2018) 132 (Supplement 1): 1198.
https://doi.org/10.1182/blood-2018-99-112567
Published: 2018
Journal Articles

Phase 1/2 Trial of Subcutaneously Administered Factor IX Variant CB2679d/ISU304: Pharmacokinetics and Activity

Free
Chur Woo You, MDPhD, Ho-Jin Shin, MD, Howard Levy, MBBCh, PhD, Martin Lee, PhD, Seung-Beom Hong, PhD, Jamie Ellen Siegel, MD, June Young Park, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 87.
https://doi.org/10.1182/blood.V130.Suppl_1.87.87
Published: 2017
Journal Articles

Oral Carbon Monoxide Therapy in Murine Models of Sickle Cell Disease: Beneficial Effects on Vaso-Occlusion, Inflammation and Anemia

Free
John D Belcher, PhD, Edward Gomperts, MD, Julia Nguyen, BS, Chunsheng Chen, MD, Fuad Abdulla, Hao Nguyen, Tran Vo, Karina Bursch, Zachary M Kiser, PhD, Howard Levy, MDPhD, Leo E Otterbein, PhD, Gregory M Vercellotti, MD FACP
Journal: Blood
Blood (2017) 130 (Supplement 1): 2232.
https://doi.org/10.1182/blood.V130.Suppl_1.2232.2232
Published: 2017
Journal Articles

Pharmacokinetics of Subcutaneously Administered CB2679d/ISU304 in Wild-Type and Hemophilia B Mice

Free
Seung-Beom Hong, PhD, Howard Levy, MBBChir, PhD, Jae Yong Jung, MS, Minkyung Park, AS, A Rim Seo, AS, So Hyeon Seo, MS, Ed Madison, PhD
Journal: Blood
Blood (2016) 128 (22): 1389.
https://doi.org/10.1182/blood.V128.22.1389.1389
Published: 2016